• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Kyverna Therapeutics Inc.

    2/6/26 3:17:11 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KYTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Kyverna Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)


    501976104

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    501976104


    1Names of Reporting Persons

    Westlake BioPartners Fund I, L.P. ("Westlake Fund I")
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,787,940.00
    6Shared Voting Power

    3,787,940.00
    7Sole Dispositive Power

    3,787,940.00
    8Shared Dispositive Power

    3,787,940.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,787,940.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Row 5 - 3,787,940 shares, except that Westlake BioPartners GP I, LLC ("Westlake GP I"), the general partner of Westlake BioPartners Fund I, L.P. ("Westlake Fund I"), may be deemed to have sole voting power, and Dr. Beth C. Seidenberg ("Seidenberg"), the managing director of Westlake GP I, may be deemed to have sole power to vote these shares. Row 7 - 3,787,940 shares, except that Westlake GP I, the general partner of Westlake Fund I, may be deemed to have sole dispositive power, and Seidenberg, the managing director of Westlake GP I, may be deemed to have sole power to dispose of these shares.


    SCHEDULE 13G

    CUSIP No.
    501976104


    1Names of Reporting Persons

    Westlake BioPartners GP I, LLC ("Westlake GP I")
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,787,940.00
    6Shared Voting Power

    3,787,940.00
    7Sole Dispositive Power

    3,787,940.00
    8Shared Dispositive Power

    3,787,940.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,787,940.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Row 5 - 3,787,940 shares, all of which are owned directly by Westlake Fund I. Westlake GP I, the general partner of Westlake Fund I, may be deemed to have sole voting power, and Seidenberg, the managing director of Westlake GP I, may be deemed to have sole power to vote these shares. Row 7 - 3,787,940 shares, all of which are owned directly by Westlake Fund I. Westlake GP I, the general partner of Westlake Fund I, may be deemed to have sole dispositive power, and Seidenberg, the managing director of Westlake GP I, may be deemed to have sole power to dispose of these shares.


    SCHEDULE 13G

    CUSIP No.
    501976104


    1Names of Reporting Persons

    Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity Fund I")
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    869,317.00
    6Shared Voting Power

    869,317.00
    7Sole Dispositive Power

    869,317.00
    8Shared Dispositive Power

    869,317.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    869,317.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.5 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Row 5 - 869,317 shares, except that Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"), the general partner of Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity Fund I"), may be deemed to have sole voting power, and Seidenberg, the managing director of Westlake Opportunity GP I, may be deemed to have sole power to vote these shares. Row 7 - 869,317 shares, except that Westlake Opportunity GP I, the general partner of Westlake Opportunity Fund I, may be deemed to have sole dispositive power, and Seidenberg, the managing director of Westlake Opportunity GP I, may be deemed to have sole power to dispose of these shares.


    SCHEDULE 13G

    CUSIP No.
    501976104


    1Names of Reporting Persons

    Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I")
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    869,317.00
    6Shared Voting Power

    869,317.00
    7Sole Dispositive Power

    869,317.00
    8Shared Dispositive Power

    869,317.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    869,317.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.5 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Row 5 - 869,317 shares, all of which are owned directly by Westlake Opportunity Fund I. Westlake Opportunity GP I, the general partner of Westlake Opportunity Fund I, may be deemed to have sole voting power, and Seidenberg, the managing director of Westlake Opportunity GP I, may be deemed to have sole power to vote these shares. Row 7 - 869,317 shares, all of which are owned directly by Westlake Opportunity Fund I. Westlake Opportunity GP I, the general partner of Westlake Opportunity Fund I, may be deemed to have sole dispositive power, and Seidenberg, the managing director of Westlake Opportunity GP I, may be deemed to have sole power to dispose of these shares.


    SCHEDULE 13G

    CUSIP No.
    501976104


    1Names of Reporting Persons

    Dr. Beth C. Seidenberg ("Seidenberg")
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,657,257.00
    6Shared Voting Power

    4,657,257.00
    7Sole Dispositive Power

    4,657,257.00
    8Shared Dispositive Power

    4,657,257.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,657,257.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Row 5 - 4,657,257 shares, of which 3,787,940 shares are owned directly by Westlake Fund I and 869,317 shares are owned directly by Westlake Opportunity Fund I. Westlake GP I and Westlake Opportunity GP I, the general partners of Westlake Fund I and Westlake Opportunity Fund I, respectively, may be deemed to have sole voting power over such shares, and Seidenberg, the managing director of Westlake GP I and Westlake Opportunity GP I, may be deemed to have sole power to vote these shares. Row 7 - 4,657,257 shares, of which 3,787,940 shares are owned directly by Westlake Fund I and 869,317 shares are owned directly by Westlake Opportunity Fund I. Westlake GP I and Westlake Opportunity GP I, the general partners of Westlake Fund I and Westlake Opportunity Fund I, respectively, may be deemed to have sole dispositive power over such shares, and Seidenberg, the managing director of Westlake GP I and Westlake Opportunity GP I, may be deemed to have sole power to dispose of these shares.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Kyverna Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    5980 Horton St., STE 550, Emeryville, CA 94608
    Item 2. 
    (a)Name of person filing:

    This Statement is being filed by Westlake BioPartners Fund I, L.P. ("Westlake Fund I"), Westlake BioPartners GP I, LLC ("Westlake GP I"), Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity Fund I") and Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I" and together with Westlake Fund I, Westlake GP I and Westlake Opportunity Fund I, the "Reporting Entities") and Dr. Beth C. Seidenberg ("Seidenberg") (the "Reporting Individual"). The Reporting Entities and the Reporting Individual are collectively referred to as the "Reporting Persons." Dr. Sean E. Harper, a Reporting Person on the initial Schedule 13G with respect to the Issuer, is no longer a managing director of Westlake GP I and Westlake Opportunity GP I, and accordingly, is not a Reporting Person on this Schedule 13G Amendment No. 1.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each Reporting Person is c/o Westlake BioPartners, LLC, 3075 Townsgate Road, Suite 140, Westlake Village, California 91361.
    (c)Citizenship:

    Each of Westlake GP I and Westlake Opportunity GP I is a limited liability company organized under the laws of the State of Delaware. Each of Westlake Fund I and Westlake Opportunity Fund I is a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, par value $0.00001 per share
    (e)CUSIP No.:

    501976104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person.*
    (b)Percent of class:

    See Row 11 of the cover page for each Reporting Person.*
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of the cover page for each Reporting Person.*

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of the cover page for each Reporting Person.*

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of the cover page for each Reporting Person.*

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of the cover page for each Reporting Person.* * Except to the extent of a Reporting Person's pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Under certain circumstances set forth in the limited partnership agreement of each of Westlake Fund I and Westlake Opportunity Fund I and the limited liability company agreement of each of Westlake GP I and Westlake Opportunity GP I, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Westlake BioPartners Fund I, L.P. ("Westlake Fund I")
     
    Signature:/s/ Jennifer L. Kercher
    Name/Title:Jennifer L. Kercher/Attorney-in-Fact*, Westlake BioPartners GP I, LLC, Its General Partner
    Date:02/05/2026
     
    Westlake BioPartners GP I, LLC ("Westlake GP I")
     
    Signature:/s/ Jennifer L. Kercher
    Name/Title:Jennifer L. Kercher/Attorney-in-Fact*
    Date:02/05/2026
     
    Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity Fund I")
     
    Signature:/s/ Jennifer L. Kercher
    Name/Title:Jennifer L. Kercher/Attorney-in-Fact*, Westlake BioPartners Opportunity GP I, LLC, Its General Partner
    Date:02/05/2026
     
    Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I")
     
    Signature:/s/ Jennifer L. Kercher
    Name/Title:Jennifer L. Kercher/Attorney-in-Fact*
    Date:02/05/2026
     
    Dr. Beth C. Seidenberg ("Seidenberg")
     
    Signature:/s/ Jennifer L. Kercher
    Name/Title:Jennifer L. Kercher/Attorney-in-Fact*
    Date:02/05/2026

    Comments accompanying signature:  * This Schedule 13G was executed pursuant to a Power of Attorney. Note that copies of the applicable Powers of Attorney are included herein as exhibits to this Schedule 13G.
    Exhibit Information

    Exhibit 1 Joint Filing Agreement 2 Power of Attorney - Westlake BioPartners Fund I, L.P. and Westlake BioPartners GP I, LLC 3 Power of Attorney - Westlake BioPartners Opportunity Fund I, L.P. and Westlake BioPartners Opportunity GP I, LLC

    Get the next $KYTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KYTX

    DatePrice TargetRatingAnalyst
    8/20/2025Outperform
    William Blair
    5/27/2025$5.00Neutral → Buy
    H.C. Wainwright
    10/10/2024$13.00Buy
    UBS
    10/9/2024$16.00Buy
    Rodman & Renshaw
    7/3/2024$8.00Neutral
    H.C. Wainwright
    3/4/2024$40.00Overweight
    Morgan Stanley
    3/4/2024$39.00Overweight
    JP Morgan
    3/4/2024$44.00Overweight
    Wells Fargo
    More analyst ratings

    $KYTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Kyverna Therapeutics

    William Blair initiated coverage of Kyverna Therapeutics with a rating of Outperform

    8/20/25 8:57:26 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Kyverna Therapeutics from Neutral to Buy and set a new price target of $5.00

    5/27/25 9:06:20 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS initiated coverage on Kyverna Therapeutics with a new price target

    UBS initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $13.00

    10/10/24 7:37:04 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Seidenberg Beth C bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:43:43 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Westlake Biopartners Opportunity Fund I, L.P. bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:42:37 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Kyverna Therapeutics Inc.

    SCHEDULE 13G/A - Kyverna Therapeutics, Inc. (0001994702) (Subject)

    2/6/26 3:17:11 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)

    2/3/26 8:00:25 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)

    1/12/26 8:00:28 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $KYTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

    EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), effective February 9, 2026. Mr. Pujols brings more than 30 years of technical operations experience to the role with a deep background in leading late-stage and commercial manufacturing for cell and gene therapies. His work spans both large-scale and smaller biopharmaceutical companies with a proven track record of successfully advancing programs across their lifecycles. He succeeds Karen Walker, who is

    2/3/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

    Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026  First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis (gMG) Completed follow-on offering extends cash runway into 2028, expected to fully fund SPS BLA filing, commercial launch, and Phase 3 gMG trial Kyverna Board member, Christi Shaw, appointed as Executive Chairperson, further bolstering Company's CAR T commercialization experience; Ian Clark, former Chairperson, to remain on Board EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. ((Kyver

    1/12/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

    EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14th, 2026, at 9:45 a.m. PT. A live audio webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference. About Kyverna TherapeuticsKyverna Therapeutics, In

    1/5/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Pujols Mayobanex

    3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    2/11/26 4:30:27 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Technology Officer Pujols Mayobanex

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    2/11/26 4:30:05 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Executive Chairperson Shaw Christi was granted 54,301 shares, increasing direct ownership by 326% to 70,935 units (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    1/14/26 5:00:10 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Financials

    Live finance-specific insights

    View All

    Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

    Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026  Miv-cel achieved statistically significant clinical benefit across all primary and secondary endpoints, reversing disability and eliminating immunotherapies after a single dose Miv-cel was generally well-tolerated with no high-grade CRS or ICANS observed SPS is a debilitating, progressive autoimmune disease with no FDA-approved therapies Company to host webcast today, December 15, 2025 at 8 am ET EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a c

    12/15/25 6:30:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

    EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 am ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS). Conference Call Details Participants will need to register at the below-noted URL in order to listen and participate in the call. Once registered, participants will receive a dial-in phone number and unique PIN number which will be needed to join th

    12/14/25 2:30:00 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

    Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically meaningful responses in MG-ADL and QMG -- the co-primary endpoints of the Phase 3 trial -- with mean reductions of -8.0 pts and -7.7 points at 24 weeks KYV-101 was well-tolerated with no high-grade CRS and no ICANS observed, further supporting the consistent and manageable safety profile of KYV-101 Unprecedented results further reinforce KYV-101's potential to deliver durable, drug-free, disease-free remission with a single dose Company to host conference call today, October 29, 2025, at 8:0

    10/29/25 6:30:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Kyverna Therapeutics Inc.

    SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)

    11/12/24 7:23:31 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Kyverna Therapeutics Inc.

    SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)

    10/10/24 12:36:27 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Kyverna Therapeutics Inc.

    SC 13D - Kyverna Therapeutics, Inc. (0001994702) (Subject)

    5/3/24 5:57:02 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYTX
    Leadership Updates

    Live Leadership Updates

    View All

    Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

    EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), effective February 9, 2026. Mr. Pujols brings more than 30 years of technical operations experience to the role with a deep background in leading late-stage and commercial manufacturing for cell and gene therapies. His work spans both large-scale and smaller biopharmaceutical companies with a proven track record of successfully advancing programs across their lifecycles. He succeeds Karen Walker, who is

    2/3/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) andBLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to initiate by year-end 2025; interim Phase 2 data expected in Q4 2025 Strong cash position to support upcoming milestones EMERYVILLE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the quarter ended June 30, 2025.   "The second quarter was

    8/12/25 4:02:00 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

    Webcast to be held August 28, 2025, 11:00am ET EMERYVILLE, Calif., July 29, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that the Company will host a webcast event with Key Opinion Leaders (KOLs) to discuss its neuroimmunology franchise. The event will take place on Thursday, August 28, 2025, from 11:00am to 1:30pm ET. Presentations will feature members of the Company's management team and the following renowned KOLs: Srikanth Muppidi, M.D., Stanford MedicineRicardo Grieshaber-Bouyer, M.D., Ph.D., FAU Erlangen-NümbergAiden Haghiki

    7/29/25 8:30:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care